ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for ...
“We are pleased to share these two recent publications featuring nonclinical findings that provide evidence of nomlabofusp’s mechanism of action, its ability to increase FXN levels in disease-relevant ...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...
- Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results